查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1362911

感染疾病物市场规模、份额和趋势分析报告：按类型/药物类别、给药途径、配销通路管道、地区和细分市场预测，2023-2030年

Anti-infective Agents Market Size, Share & Trends Analysis Report By Type/Drug Class (Antivirals, Antifungals), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 - 2030
出版日期: | 出版商: Grand View Research | 英文 120 Pages | 商品交期: 2-10个工作天内

价格

感染疾病物市场成长及趋势：

Grand View Research, Inc.最新报告显示，预计到2030年，全球感染疾病物市场规模将达到1506亿美元，2023年至2030年年复合成长率为1.2%。

HIV、H1N1 和伊波拉病毒等感染疾病的日益流行反映了近几十年来社区行为模式的重大变化。社会变迁以及医疗保健专业人员和患者意识的提高正在推动成长。

世界卫生组织 (WHO) 和疾病管制与预防中心 (CDC) 等组织正在积极努力提高公众对感染疾病致命影响和早期治疗重要性的认识。 CDC 正在与国家卫生署(NHM) 合作，在巴西、中国、奈及利亚和印度等开发中国家宣传感染疾病的治疗。

然而，研发线产品的商业化，例如效力和功效增强的新疗法的推出，以及2018年用于治疗社区获得性细菌性肺炎（CABP）的omadacycline的商业化，预计将推动该领域的增长感染疾病物市场。

感染疾病物市场报告亮点

  • 由于爱滋病毒药物 vicriviroc 等新型强效抗病毒药物价格高昂，预计抗病毒药物将成为最大的细分市场，到 2022 年，市场占有率将达到 53.2%。
  • 抗生素领域预计在预测期内复合年复合成长率最快，达到 4.2%。抗生素已商业化，增加了处方数量并增加了可用性，预计这将进一步推动该领域。
  • 用于治疗和预防严重和危及生命的感染疾病的组合药物的开发预计将加速感染疾病物的使用。例如，2012年，吉利德科学公司推出了包含四种药物（考比司他、艾替拉韦、恩曲他滨和富马酸替诺福韦二吡呋酯）的综合治疗方法，用于治疗未接受过逆转录病毒治疗的爱滋病患者。我们也发布了一款新产品。
  • 由于新产品的开发和强大的产品平臺的存在，口服给药途径预计将在 2022 年成为最大的细分市场。
  • 医院药局以 2022 年收益占有率最高的 28.8% 占据市场主导地位，预计电子商务将成为预测期内成长最快的领域。
  • 2022年，北美地区在全球产业中占据主导地位，占最大份额，占总收益的37.0%。感染疾病（包括儿童和成人的医院感染）的高盛行率以及由此导致的抗生素过度使用和非处方笺抗感染药物的获取增加是主要促进因素。
  • 由于对新药的大量未满足的需求、快速发展的医疗基础设施以及医疗保健专业人员和患者的意识不断提高，亚太地区是成长最快的地区之一。
  • 有效的疾病管理需要多种长期策略，包括新产品开发、併购、共同开发和业务扩张。例如，2015年，ReViral从Wellcome Trust获得2,100万美元资金用于开发RV521。

目录

第1章调查方法与范围

第2章执行摘要

第3章感染疾病市场变数、趋势、范围

  • 市场体系预测
    • 母市场预测
    • 相关/附随市场预测
  • 普及和成长预测图
  • 市场动态
    • 市场促进因素分析
    • 市场抑制因素分析
  • 感染疾病物市场分析工具
    • 产业分析-波特五力分析
    • PESTEL分析

第4章感染疾病：种类/药物类别的估计与趋势分析

  • 感染疾病物市场：重点
  • 感染疾病物市场：2022年和2030年趋势和市场占有率分析
  • 抗菌剂
    • 2018-2030年抗菌剂市场预估及预测
    • 2018年至2030年抗菌剂类市场估计与预测
  • 抗病毒药物
    • 2018年至2030年抗病毒药物市场估计与预测
  • 抗真菌药物
    • 2018年至2030年抗真菌药物市场估计与预测
    • 2018年至2030年抗真菌药物类市场估计与预测

第5章感染疾病市场：给药途径预估及趋势分析

  • 感染疾病物市场：重点
  • 感染疾病物市场：2022年和2030年趋势和市场占有率分析
  • 局部的
  • 口服
  • Ⅳ
  • 其他的

第6章感染疾病市场：配销通路估算及趋势分析

  • 感染疾病物市场：重点
  • 感染疾病物市场：2022年和2030年趋势和市场占有率分析
  • 医院药房
  • 零售药房
  • 专业药房
  • 电子商务
  • 其他的

第7章感染疾病市场：区域估算及趋势分析

  • 区域预测
  • 感染疾病物市场（按区域）：重点
  • 北美洲
    • 2018-2030 年市场估计与预测
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 瑞典
    • 挪威
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 泰国
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第8章竞争形势

  • 主要市场参与企业的最新趋势和影响分析
  • 市场参与企业分类
    • Pfizer Inc.
    • Abbott.
    • Gilead Sciences, Inc.
    • Bristol-Myers Squibb Company
    • Merck & Co., Inc.
    • Sandoz International GmbH
    • B. Braun SE
    • Xellia Pharmaceuticals
    • Mankind Pharma
    • Bayer AG
    • AstraZeneca
    • Boehringer Ingelheim International GmbH.
Product Code: 978-1-68038-973-9

Anti-infective Agents Market Growth & Trends:

The global anti-infective agents market size is expected to reach USD 150.6 billion by 2030, registering a CAGR of 1.2% from 2023 to 2030, according to a new report by Grand View Research, Inc.. Rising prevalence of infectious diseases such as HIV, H1N1, and Ebola virus reflect the profound changes in behavioral patterns of communities over the recent decades. The societal changes and increasing awareness among healthcare professionals and patients are driving the growth.

Organizations, such as the World Health Organization (WHO) and Centers for Disease control and Prevention (CDC) are actively involved in spreading awareness amongstpeople regarding the fatal implications of infectious diseases and the importance of early treatment. The CDC has collaborated with the National Health Ministry (NHM) in an attempt to spread awareness and to enhance the treatment of communicable diseases in developing countries such as Brazil, China, Nigeria, and India.

However, introduction of novel therapeutics with increased potency and efficacy and the commercialization of pipeline products, such as commercialization of Omadacycline in 2018 for the treatment of Community Acquired Bacterial Pneumonia (CABP), are expected to propel the growth of the anti-infective agents market.

Anti-infective Agents Market Report Highlights:

  • Antiviral was estimated to be the largest segment with a market share of 53.2% in 2022 owing to the high price associated with the new potent anti-viral drugs, such as Vicriviroc for the treatment of HIV
  • Antibacterial segment is anticipated to register the fastest CAGR of 4.2% during the forecast period, as antibacterial is the first line of treatment for a large range of infections. Increased prescription and accessibility of antibacterial due to their over-the-counter status is anticipated to further drive the segment
  • Development of combination drugs to treat and prevent serious and life-threatening infections is expected to propel the usage of anti-infective drugs. For instance, in 2012, Gilead Sciences, Inc. launched Stribild, a comprehensive treatment regimen inclusive of four drugs (cobicistat, elvitegravir, emtricitabine, and tenofovir disoproxil fumarate) used for the treatment of HIV patients without prior retroviral treatment record
  • Oral route of administration was estimated to be the held largest segment in 2022 owing to new product development and presence of strong product pipeline
  • Hospital pharmacy dominated the market with the highest revenue share of 28.8% in 2022 while e-commerce is expected to be the fastest-growing segment during the forecast period
  • North America dominated the global industry in 2022 and accounted for the largest share of 37.0% of the overall revenue. High prevalence of infectious diseases including hospital-acquired infections in both, children and adults, and the resultant overuse of antibiotics coupled with increased accessibility of non-prescription anti-infectives are the major drivers
  • Asia Pacific is one of the fastest growing regional segments owing to the presence of high, unmet demand for novel drugs, rapid improvements in healthcare infrastructure coupled with rising awareness among healthcare professionals and patients
  • Effective disease management involves a range of long-term strategies such as new product development, mergers and acquisitions, co-development, and business expansions. For instance, in 2015, ReViral received funding of USD 21 million for the development of its RV521 drug by the Wellcome Trust.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Type
    • 1.1.2. Route of Administration
    • 1.1.3. Distribution Channel
    • 1.1.4. Regional scope
    • 1.1.5. Estimates and forecast timeline
  • 1.2. Research Methodology
  • 1.3. Information Procurement
    • 1.3.1. Purchased database
    • 1.3.2. GVR's internal database
    • 1.3.3. Secondary route of administrations
    • 1.3.4. Primary research
    • 1.3.5. Details of primary research
  • 1.4. Information or Data Analysis
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
  • 1.7. List of Secondary Sources
  • 1.8. List of Primary Sources
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Type outlook
    • 2.2.2. Route of administration outlook
    • 2.2.3. Distribution channel outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Anti-Infective Agents Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
    • 3.3.2. Market Restraint Analysis
  • 3.4. Anti-Infective Agents Market Analysis Tools
    • 3.4.1. Industry Analysis - Porter's
      • 3.4.1.1. Supplier power
      • 3.4.1.2. Buyer power
      • 3.4.1.3. Substitution threat
      • 3.4.1.4. Threat of new entrant
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Technological landscape
      • 3.4.2.3. Economic Landscape

Chapter 4. Anti-Infective Agents: Type/Drug Class Estimates & Trend Analysis

  • 4.1. Anti-Infective Agents Market: Key Takeaways
  • 4.2. Anti-Infective Agents Market: Movement & Market Share Analysis, 2022 & 2030
  • 4.3. Antibacterials
    • 4.3.1. Antibacterials market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.3.2. Antibacterials drug class market estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.3.2.1. Cephalosporins
      • 4.3.2.1.1 Cephalosporins market estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.3.2.2. Penicillin
      • 4.3.2.2.1 Penicillin market estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.3.2.3. Fluoroquinolones
      • 4.3.2.2.2 Fluoroquinolones market estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.3.2.3 Macrolides
      • 4.3.2.3.1 Macrolides market estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.3.2.4 Carbapenem
      • 4.3.2.4.1 Carbapenem market estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.3.2.5 Others
      • 4.3.2.5.1 Others market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 4.4. Antivirals
    • 4.4.1. Antivirals market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 4.5. Antifungals
    • 4.5.1. Antifungals market estimates and forecasts, 2018 to 2030 (USD Billion)
    • 4.5.2. Antifungals drug class market estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.5.2.1. Azoles
      • 4.5.2.1.2 Azoles market estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.5.2.2. Echinocandins
      • 4.5.2.2.3 Echinocandins market estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.5.2.3. Polyenes
      • 4.5.2.2.4 Polyenes market estimates and forecasts, 2018 to 2030 (USD Billion)
      • 4.5.2.3 Others
      • 4.5.2.3.1 Others market estimates and forecasts, 2018 to 2030 (USD Billion)

Chapter 5. Anti-Infective Agents Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Anti-Infective Agents Market: Key Takeaways
  • 5.2. Anti-Infective Agents Market: Movement & Market Share Analysis, 2022 & 2030
  • 5.3. Topical
    • 5.3.1. Topical market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 5.4. Oral
    • 5.4.1. Oral market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 5.5. IV
    • 5.5.1. IV market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 5.6. Others
    • 5.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Billion)

Chapter 6. Anti-Infective Agents Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Anti-Infective Agents Market: Key Takeaways
  • 6.2. Anti-Infective Agents Market: Movement & Market Share Analysis, 2022 & 2030
  • 6.3. Hospital Pharmacies
    • 6.3.1. Hospital pharmacies market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail pharmacies market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 6.5. Specialty Pharmacies
    • 6.5.1. Specialty pharmacies market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 6.6. E-Commerce
    • 6.6.1. Specialty pharmacies market estimates and forecasts, 2018 to 2030 (USD Billion)
  • 6.7. Others
    • 6.7.1. Other market estimates and forecasts, 2018 to 2030 (USD Billion)

Chapter 7. Anti-Infective Agents Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Outlook
  • 7.2. Anti-Infective Agents Market by Region: Key Takeaways
  • 7.3. North America
    • 7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.3.2. U.S.
      • 7.3.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.3.3. Canada
      • 7.3.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.4.2. Germany
      • 7.4.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.4.3. France
      • 7.4.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.4.4. Italy
      • 7.4.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.4.5. Spain
      • 7.4.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.4.6. Sweden
      • 7.4.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.4.7. Norway
      • 7.4.7.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.4.8. Denmark
      • 7.4.8.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.5.2. China
      • 7.5.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.5.3. India
      • 7.5.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.5.4. Australia
      • 7.5.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.5.5. Thailand
      • 7.5.5.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.5.6. South Korea
      • 7.5.6.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.6.2. Mexico
      • 7.6.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.6.3. Argentina
      • 7.6.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.7.3. UAE
      • 7.7.3.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)
    • 7.7.4. Kuwait
      • 7.7.4.1. Market estimates and forecasts, 2018 - 2030 (Revenue, USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Market Participant Categorization
    • 8.2.1. Pfizer Inc.
      • 8.2.1.1. Company overview
      • 8.2.1.2. Financial performance
      • 8.2.1.3. Product benchmarking
      • 8.2.1.4. Strategic initiatives
    • 8.2.2. Abbott.
      • 8.2.2.1. Company overview
      • 8.2.2.2. Financial performance
      • 8.2.2.3. Product benchmarking
      • 8.2.2.4. Strategic initiatives
    • 8.2.3. Gilead Sciences, Inc.
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Bristol-Myers Squibb Company
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Merck & Co., Inc.
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. Sandoz International GmbH
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. B. Braun SE
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Xellia Pharmaceuticals
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. Mankind Pharma
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. Bayer AG
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Product benchmarking
      • 8.2.10.4. Strategic initiatives
    • 8.2.11. AstraZeneca
      • 8.2.11.1. Company overview
      • 8.2.11.2. Financial performance
      • 8.2.11.3. Product benchmarking
      • 8.2.11.4. Strategic initiatives
    • 8.2.12. Boehringer Ingelheim International GmbH.
      • 8.2.12.1. Company overview
      • 8.2.12.2. Financial performance
      • 8.2.12.3. Product benchmarking
      • 8.2.12.4. Strategic initiatives

List of Tables

  • Table 1 List of Abbreviations
  • Table 2 North America anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 3 North America anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 4 North America anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 5 North America anti-infective agents market, by region, 2018 - 2030 (USD Billion)
  • Table 6 U.S. anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 7 U.S. anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 8 U.S. anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 9 Canada anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 10 Canada anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 11 Canada anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 12 Europe anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 13 Europe anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 14 Europe anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 15 Europe anti-infective agents market, by region, 2018 - 2030 (USD Billion)
  • Table 16 Germany anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 17 Germany anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 18 Germany anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 19 UK anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 20 UK anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 21 UK anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 22 France anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 23 France anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 24 France anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 25 Italy anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 26 Italy anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 27 Italy anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 28 Spain anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 29 Spain anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 30 Spain anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 31 Sweden anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 32 Sweden anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 33 Sweden anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 34 Norway anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 35 Norway anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 36 Norway anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 37 Denmark anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 38 Denmark anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 39 Denmark anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 40 Asia Pacific anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 41 Asia Pacific anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 42 Asia Pacific anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 43 Asia Pacific anti-infective agents market, by region, 2018 - 2030 (USD Billion)
  • Table 44 Japan anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 45 Japan anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 46 Japan anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 47 China anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 48 China anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 49 China anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 50 India anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 51 India anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 52 India anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 53 Australia anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 54 Australia anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 55 Australia anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 56 Thailand anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 57 Thailand anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 58 Thailand anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 59 South Korea anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 60 South Korea anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 61 South Korea anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 62 Latin America anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 63 Latin America anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 64 Latin America anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 65 Latin America anti-infective agents market, by region, 2018 - 2030 (USD Billion)
  • Table 66 Brazil anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 67 Brazil anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 68 Brazil anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 69 Mexico anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 70 Mexico anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 71 Mexico anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 72 Argentina anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 73 Argentina anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 74 Argentina anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 75 Middle East and Africa anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 76 Middle East and Africa anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 77 Middle East and Africa anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 78 Middle East and Africa anti-infective agents market, by region, 2018 - 2030 (USD Billion)
  • Table 79 South Africa anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 80 South Africa anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 81 South Africa anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 82 Saudi Arabia anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 83 Saudi Arabia anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 84 Saudi Arabia anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 85 UAE anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 86 UAE anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 87 UAE anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)
  • Table 88 Kuwait anti-infective agents market, by type, 2018 - 2030 (USD Billion)
  • Table 89 Kuwait anti-infective agents market, by route of administration, 2018 - 2030 (USD Billion)
  • Table 90 Kuwait anti-infective agents market, by distribution channel, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Anti-infective agents: Market outlook
  • Fig. 9 Anti-infective agents: Competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 Industry value chain analysis
  • Fig. 14 Anti-infective agents market driver impact
  • Fig. 15 Anti-infective agents market restraint impact
  • Fig. 16 Anti-infective agents market strategic Initiatives analysis
  • Fig. 17 Anti-infective agents market: Type movement analysis
  • Fig. 18 Anti-infective agents market: Type outlook and key takeaways
  • Fig. 19 Antibacterials market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 20 Antibacterials drug class market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 21 Cephalosporins market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 22 Penicillin market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 23 Fluoroquinolones market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 24 Macrolides market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 25 Carbapenems market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 26 Others market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 27 Antivirals market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 28 Antifungals market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 29 Cephalosporins market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 30 Penicillin market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 31 Fluoroquinolones market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 32 Macrolides market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 33 Carbapenems market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 34 Others market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 35 Anti-infective agents market: Route of administration movement analysis
  • Fig. 36 Anti-infective agents market: Route of administration outlook and key takeaways
  • Fig. 37 Topical market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 38 Oral market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 39 IV market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 40 Others market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 41 Anti-infective agents market: Distribution channel movement analysis
  • Fig. 42 Anti-infective agents market: Distribution channel outlook and key takeaways
  • Fig. 43 Hospital pharmacies market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 44 Retail pharmacies market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 45 Specialty pharmacies market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 46 E-commerce market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 47 Others market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 48 Global anti-infective agents market: Regional movement analysis
  • Fig. 49 Global anti-infective agents market: Regional outlook and key takeaways
  • Fig. 50 North America market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 51 U.S. market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 52 Canada market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 53 Europe. market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 54 UK market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 55 Germany market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 56 France market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 57 Italy market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 58 Spain market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 59 Sweden market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 60 Norway market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 61 Denmark market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 62 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 63 Japan market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 64 China market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 65 India market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 66 Australia market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 67 Thailand market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 68 South Korea market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 69 Latin America market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 70 Brazil market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 71 Mexico market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 72 Argentina market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 73 Middle East and Africa. market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 74 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 75 South Africa market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 76 UAE market estimates and forecasts, 2018 - 2030 (USD Billion)
  • Fig. 77 Kuwait market estimates and forecasts, 2018 - 2030 (USD Billion)